PMID- 29424412
OWN - NLM
STAT- MEDLINE
DCOM- 20180330
LR  - 20180330
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 145
IP  - 9
DP  - 2017 Sep
TI  - [Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report].
PG  - 1213-1217
LID - S0034-98872017000901213 [pii]
LID - 10.4067/s0034-98872017000901213 [doi]
AB  - Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more 
      frequently with unfractionated heparin (UFH) than with low molecular weight 
      heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic 
      events, as opposed to thrombocytopenia of other etiologies. The key in therapy is 
      the cessation of heparin and the start of another anticoagulant. We report a 58 
      years old female with HIT secondary to the use of Enoxaparin who was successfully 
      managed with Rivaroxaban. Our goal is to report a novel therapy and provide the 
      evidence that supports its use.
FAU - Rivera O, Gustavo
AU  - Rivera O G
AD  - Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Corsi S, Oscar
AU  - Corsi S O
AD  - Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad 
      Catolica de Chile, Santiago, Chile.
FAU - Pavlovic J, Andres
AU  - Pavlovic J A
AD  - Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Aizman S, Andres
AU  - Aizman S A
AD  - Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad 
      Catolica de Chile, Santiago, Chile.
FAU - Varas A, Pablo
AU  - Varas A P
AD  - Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad 
      Catolica de Chile, Santiago, Chile.
LA  - spa
PT  - Case Reports
PT  - Journal Article
TT  - Rivaroxaban para el tratamiento de la trombocitopenia inducida por heparina. Caso 
      clinico.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
SB  - IM
MH  - Anticoagulants/*adverse effects
MH  - Factor Xa Inhibitors/*therapeutic use
MH  - Female
MH  - Heparin/*adverse effects
MH  - Humans
MH  - Middle Aged
MH  - Risk Factors
MH  - Rivaroxaban/*therapeutic use
MH  - Thrombocytopenia/*chemically induced/*drug therapy
MH  - Treatment Outcome
MH  - Venous Thrombosis/etiology/prevention & control
EDAT- 2018/02/10 06:00
MHDA- 2018/03/31 06:00
CRDT- 2018/02/10 06:00
PHST- 2017/06/13 00:00 [received]
PHST- 2017/08/29 00:00 [accepted]
PHST- 2018/02/10 06:00 [entrez]
PHST- 2018/02/10 06:00 [pubmed]
PHST- 2018/03/31 06:00 [medline]
AID - S0034-98872017000901213 [pii]
AID - 10.4067/s0034-98872017000901213 [doi]
PST - ppublish
SO  - Rev Med Chil. 2017 Sep;145(9):1213-1217. doi: 10.4067/s0034-98872017000901213.